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Survivin is an apoptotic inhibitor that is expressed at high levels in a variety of malignancies. Survivin has four known alternative splice
forms (Survivin, Survivin-2B, Survivin-deltaEx3, and Survivin-3B), and the recent literature suggests that these splice variants have
unique functions and subcellular localisation patterns. We evaluated 19 fresh-frozen paediatric medulloblastomas for the expression
of three Survivin isoforms by quantitative PCR. Survivin was most highly expressed when compared with normal cerebellar tissue.
We also investigated Survivin protein expression in 40 paraffin-embedded paediatric medulloblastoma tumours by
immunohistochemistry. We found a statistically significant association between the percentage of Survivin-positive cells and
histologic subtype, with the large-cell-anaplastic variant expressing Survivin at higher levels than the classic subtype. We also found a
statistically significant relationship between the percent of Survivin-positive cells in the tumours and clinical outcome, with higher
levels of Survivin correlating with a worse prognosis. In summary, our study demonstrates a role for Survivin as a marker of tumour
morphology and clinical outcome in medulloblastoma. Survivin may be a promising future prognostic tool and potential biologic
target in this malignancy.
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Medulloblastoma is the most common primary malignant central
nervous system (CNS) tumour of childhood. It is an invasive
embryonal tumour originating in the cerebellum with an inherent
tendency to metastasise within the CNS via the cerebrospinal
fluid (CSF) (Stavrou et al, 2001; Eberhart et al, 2003; Mazzola
and Pollack, 2003). There are four major histologic subtypes
of medulloblastoma including classic, desmoplastic, extremely
nodular, and large-cell-anaplastic. Each subtype has unique
histologic features and prognosis (Rickert and Paulus, 2001;
Kleihues et al, 2002). The large-cell-anaplastic variant is clinically
the most aggressive subtype, and represents between 4 and 25%
of all medulloblastomas cases (Leonard et al, 2001; Eberhart
et al, 2002).
There have been many advances in the treatment of medullo-
blastoma including improved surgical resection techniques,
radiation, and chemotherapy (Zeltzer et al, 1999; Packer et al,
2003a; Taylor et al, 2003). These changes have greatly improved
overall survival with current treatment strategies achieving up to
70–75% 5-year disease-free survival (DFS) (Evans et al, 1990;
Packer et al, 1994; Leonard et al, 2001). As a consequence of
current treatment strategies, however, patients often suffer from
life-long disabilities and cognitive dysfunction. It is estimated that
90% of medulloblastoma survivors have impaired intelligence, and
40–100% of long-term survivors have some degree of cognitive
dysfunction (Walter et al, 1999; Palmer et al, 2001; Packer et al,
2003b). Radiation and chemotherapy also often lead to significant
endocrine abnormalities, including thyroid, growth, and gonadal
dysfunction (Xu et al, 2004). High morbidity and continued
mortality have prompted the search for new treatment strategies as
well as for biologic markers that might be used for targeted therapy
to minimise current treatment-related side effects. Survivin is an
attractive target gene to evaluate for these purposes, as it has been
shown to be a significant marker of tumour aggression in a
number of malignancies (Altieri, 2003b).
The protein encoded by the Survivin gene has significant
structural homology to a group of proteins known as inhibitors of
apoptosis (IAP) (Altieri and Marchisio, 1999; Altieri, 2003a).
Survivin is expressed at high levels in numerous adult malig-
nancies including lymphomas, breast, lung, and colon carcinoma,
as well as in paediatric cancers including neuroblastoma, Wilm’s
tumour, choroid plexus tumours, and ependymomas (Altieri,
2003b; Altura et al, 2003). It is expressed widely during normal
embryonic development, but only in a small subset of adult normal
differentiated tissues, including the colonic epithelium, uterine
endometrium, vascular endothelium, and the subventricular
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sregion of normal brain (Konno et al, 2000; Gianani et al, 2001;
Altieri, 2003b; Altura et al, 2003). Survivin is expressed in a
cell-cycle-dependent manner with the highest levels of expres-
sion in G2/M (Skoufias et al, 2000). Its predominance in certain
normal and malignant tissues suggests that it has a specific
function within them. Previous reports have suggested that
the function of Survivin in cancer is predominantly as an
IAP, blocking mitochondrial-dependent apoptosis (Li et al,
1998; Altieri and Marchisio, 1999). Survivin is also involved
in a mitotic checkpoint as a chromosomal passenger protein
(CPP). This family of proteins aligns the chromosomes
appropriately during mitosis and maintains accurate cell divi-
sion in normal cells (Lens et al, 2003). It also prevents the
development of abnormal numbers of chromosomes that may
occur during the transition from a nonmalignant to a malignant
phenotype.
The human Survivin gene locus has four known splice
variants that result from alternative splicing of its messenger
RNA. It has been hypothesised that each of these isoforms
has a unique function and a unique subcellular localisation
pattern (Mahotka et al, 1999, 2002a,b). Survivin and the Sur-
vivin isoforms have been determined to be markers for
tumour aggression and clinical outcome in CNS tumours (Sasaki
et al, 2002; Katoh et al, 2003; Yamada et al, 2003). These
studies focused primarily on adult CNS tumours, and often,
tumours of two or more differing morphologies. Survivin
expression has not been previously evaluated in a series of
medulloblastoma tumours. In the current work, we evaluate the
expression of Survivin and its isoforms as potential biologic and
prognostic markers in medulloblastoma.
MATERIALS AND METHODS
Patient recruitment
Tumour samples obtained from 40 paediatric patients with
a diagnosis of medulloblastoma were selected from the
Columbus Children’s Hospital (CCH) pathology database based
on diagnosis and availability of paraffin-embedded tumour
material. All patients were treated at CCH between 1992 and
2003. Studies were performed following approval from the
CCH Internal Review Board (IRB). Treatment was based on
diagnosis and extent of surgical resection. Patients received a
combination of surgery, radiation and/or chemotherapy. Addi-
tionally, 19 fresh-frozen tumours were obtained from the
Cooperative Human tumour Network (CHTN), after approval
through the CCH IRB.
Immunohistochemistry
Paraffin-embedded tumour samples were sectioned at a thickness
of 4–5mm on a Leica microtome and placed on charged slides.
Heat antigen retrieval was performed on a pressure cooker with
Antigen Retrieval Citra (BioGenex, San Ramon, CA, USA)
according to the manufacturer’s instructions. Blocking was
performed with Powerblock for 10–15min. The samples were
incubated at 41C overnight with either the anti-Survivin primary
antibody NB-500-201 (Novus Biologicals, Littleton, CO, USA) or
the sc-10811 antibody (Santa Cruz Biotech, CA, USA). Immuno-
histochemistry was performed using the avidin–biotin method
with reagents from Biocare Medical (Walnut Creek, CA, USA).
Colour development was achieved by applying peroxidase
substrate chromagen AEC (Dako, Carpentenia, CA, USA). Slides
were counterstained with Mayer’s haematoxylin and mounted in
aqueous mounting solution (Crystal Mount, Biomeda, Foster City,
CA, USA).
Each slide was evaluated for Survivin expression by two
investigators, independently. A total of 500 cells were counted
from an overall representative and well-preserved region of the
slide. A repeat cell count was performed by the neuro-pathologist
on samples in which there was greater than a 3% difference
between the two investigators.
Western blotting
Daoy cells (ATCC #HTB-186) are human medulloblastoma cells
originally established from a medulloblastoma tumour isolated
from the posterior fossa of a 4 year-old child (Jacobsen et al, 1985).
Cells were grown in Dulbecco’s modified essential medium
supplemented with 10% fetal bovine serum and 2mML -glutamine.
Protein was extracted from Daoy cells using RIPA lysis buffer. The
SDS boiling method was used to isolate protein from fresh-frozen
tissue. Samples were homogenised with a mortar and pestle in a
heated buffer solution (1% SDS and 10mM Tris, pH 7.4). Equal
amounts of protein (150mg) were separated on an 18% SDS–PAGE
and transferred onto a nitrocellulose membrane using a semidry
transfer apparatus. The membrane was probed with the anti-
Survivin polyclonal antibodies (NB-500-201 and sc-10811)
(1:5000) and HRP-conjugated anti-rabbit IgG (1:5000). Detection
was performed using the advanced ECL System (Amersham,
Piscataway, NJ, USA).
RNA isolation
Total RNA was isolated from fresh-frozen brain tumour tissue
using RNeasy Mini Kit. Briefly, the tumour sample was weighed,
then placed in a 5  lysis buffer containing guanidine isothicya-
nate. The mixture was homogenised and purified on an RNeasy
mini column (Valencia, CA, USA).
Real-time PCR
Omniscript Reverse Transcriptase (Qiagen, Hilden, Germany) was
used to synthesise cDNA from total RNA. Real-time PCR was
performed using an ABI 7700 (Advanced Bio-systems, Foster City,
CA, USA). The sequences used for primers and probes for
Survivin-2B included the following: forward 50-GCACGGTGGCT
TACGCCTG, probe 50 FAM-ATACCAGCACTTTGGGAGG, and
reverse 50-ACCGGACGAATGCTTTTTATGTTCC. The sequences
for Survivin-deltaEx3 were forward 500-GCTGGGAGCCAGAT
GACG, probe 50 FAM-CCCCATGCAAAGGAAACCAACAATAA
GAA and reverse 50-TTCGCAGTTTCCTCAAATTCTTT. Real-time
probe sets were selected using the Primer Express program
(Applied Biosystems, Foster City, CA, USA). Probes were
labelled with FAM dye and TAMRA quencher. Each PCR reac-
tion was performed in triplicate. Ribosomal RNA was used
as an internal control for each sample. Standard curves were
constructed using serial dilutions of RNA isolates from a
medulloblastoma cell line (Daoy). The results from each sample
were compared with normal cerebellum as a calibrator using the
Relative Standard Curve method (Applied Biosystems, Foster City,
CA, USA).
Statistical methods
Data were illustrated with box plots and Kaplan–Meier curves.
Percent staining was compared across subtypes with an overall
nonparametric Kruskal–Wallis test and followed up with Wilcox
on rank sums paired comparisons. The association between per
cent staining and survival was evaluated with a Cox proportional
hazards survival test. Differences were considered statistically
significant at an alpha of 0.05.
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Expression of Survivin isoforms in medulloblastoma
We evaluated the transcriptional expression of three of the
different Survivin isoforms by quantitative PCR in 19 different
fresh-frozen medulloblastoma samples. The expression of Survi-
vin, Survivin-2B, and Survivin-deltaEx3 in the tumour samples was
quantified using the Relative Standard Curve Method and then
compared with the expression in normal cerebellum. The results
indicate that the isoforms are expressed in the majority of tumour
samples at levels that are higher than their expression in normal
cerebellum. The relative expression of Survivin, when compared to
Survivin-2B and Survivin-deltaEx3 was the highest in the majority
of tumour samples. Expression levels of Survivin in the tumours
ranged from o1 (one sample) to 278-fold above normal human
cerebellum (Figure 1). Survivin-2B levels ranged from o1( 2
samples) to 43-fold above normal human cerebellum, and levels of
Survivin-deltaEx3 ranged from o1 (4 samples) to 20-fold above
normal cerebellum (Figure 1).
To evaluate whether these isoforms were translated into stable
protein in medulloblastoma cells, Western blots were performed
on a subset of these tumour samples and on lysates made from
Daoy cells using the NB-500-201 polyclonal antibody (Figure 2).
The Western blots showed specific bands at the predicted
molecular weights for Survivin and the Survivin isoforms,
Survivin-2B and Survivin-deltaEx3, suggesting that these tran-
scripts are translated in these tumour cells. The same results were
obtained using the sc-10811 antibody (results not shown).
Patient outcome in 40 patients with medulloblastoma
Among the 40 patients with medulloblastoma, the mean and
the median ages were 8.4 and 8 years old, respectively. The
male:female ratio was 1.85:1. The medulloblastoma tumours were
classified into the following subtypes: four large-cell-anaplastic
(10%), four desmoplastic (10%), one extremely nodular (2.5%),
and 31 classic (77.5%). The median follow-up time on living


















































1 23456789 10 11 12 13 14 15 16 17 18 19
A DDDD D D D D DD AA A A AA A U
Survivin isoform expression
Figure 1 Transcriptional expression of Survivin, Survivin-2B, and Survivin-deltaEx3 in 19 fresh-frozen medulloblastoma tumours using quantitative PCR.









Figure 2 Protein expression in Daoy cells and medulloblastoma tumours. Daoy cell line and two medulloblastoma tumour samples (#18 and #19)
stained with the anti-Survivin antibody Novus-500-201 demonstrated three bands at the predicted molecular weights of Survivin, Survivin-2B, and Survivin-
deltaEx3.
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s77.5% of the original 40 patients were still alive, and the 5-year
overall survival (OS) was approximately 82% (Figure 3).
Survivin expression in medulloblastoma correlates with
morphologic subtype and clinical outcome
Evaluation of the 40 medulloblastoma tumours by immunohisto-
chemical staining (both NB-500-201 and sc-10811) showed that
Survivin localised to the nucleus in all tumour cells that expressed
Survivin (Figure 4). The percentage of positive cells ranged from
o5% to a maximum of 40%. The large-cell-anaplastic subtype
showed a higher overall percentage of positive cells (Figure 4B),
whereas the desmoplastic and extremely nodular subtypes showed
a unique pattern of Survivin staining (Figures 4C and D). The
internodular (poorly differentiated) areas had higher percentages
of Survivin staining when compared with the intranodular (highly
differentiated) regions.
The percentage of Survivin-positive cells within each sample
did not correlate with age or sex of the patient. A correlation
between morphologic subtype and percent Survivin staining
was statistically significant with the NB-500-201 antibody
(Figure 5A). As the percentage of cells staining positive for
Survivin increased, the tumour was statistically more likely to
be a large-cell-anaplastic variant. A paired comparison between
the classic undifferentiated and the large cell variant revealed
a statistically significant difference (P¼0.03). The mean percen-
tage of staining was 8–10% higher in the large-cell-anaplastic
subtype vs the classic subtype of medulloblastoma. These
results suggest that Survivin may be a marker for tumour
aggression and useful as a supplemental tool distinguishing the
large-cell-anaplastic variant from the classic medulloblastoma
subtype.
The percentage of cells staining positive for Survivin also
correlated with clinical outcome. Tumours of deceased patients
had a higher mean percentage of Survivin-positive cells when
compared with living patients (Figure 5B) (P¼0.03). This supports
a role for Survivin as a marker for clinical outcome in
medulloblastoma. When the length of time from diagnosis to
death or diagnosis to most recent follow-up was taken into
consideration, the relationship between percent staining and
survival approached, but lost, true statistical significance
(P¼0.1). This may indicate that a larger study population is
necessary to appreciate a statistically significant relationship for
this parameter.
DISCUSSION
Proteins from the IAP family play an important role in inhibiting
pathways leading to programmed cell death (Li et al, 1998; Altieri
and Marchisio, 1999; Altieri, 2003a). Although the functional roles
of Survivin and the Survivin isoforms in normal cells vs their roles
in tumourigenesis are not yet completely understood, transcrip-
tional and protein levels of Survivin and its isoforms have been
determined to correlate with tumour aggression in a variety of
malignancies, including CNS tumours (Mahotka et al, 2002b;
Altieri, 2003b; Altura et al, 2003, Kleinschmidt-DeMasters et al,
2003; Shariat et al, 2004). A study evaluating Survivin expression in
adult gliomas showed that patients with high levels of Survivin
protein expression had significantly worse clinical outcomes. The
prognostic value of Survivin expression was independent of
histology alone in this study (Chakravarti et al, 2002). Another
group evaluated the transcriptional expression of the Survivin
isoforms by quantitative PCR in primary CNS tumours. These
authors concluded that Survivin was preferentially expressed in
malignant brain tumours and gliomas when compared with benign
and nonglial tumours, respectively. They also stated that higher
expression levels of Survivin-deltaEx3 were detected in malignant
tumours, while Survivin-2B was more prominent in benign
tumours (Yamada et al, 2003). This is one of the first suggestions
that each Survivin isoform might have a unique function in CNS
tumours.
In our study, Survivin and its isoforms were expressed at much
higher levels in the medulloblastoma tumours when compared
with normal human cerebellum. This finding suggests that the
Survivin gene plays an active role in tumourigenesis in medullo-
blastoma. Quantification of the expression levels of the alternative
splice forms of Survivin in medulloblastoma compared to normal
cerebellar expression showed a predominance of Survivin com-
pared to Survivin-2B and Survivin-deltaEx3 in the 19 medullo-
blastoma samples in our study. Survivin-2B was the next highest
expressed isoform, and Survivin-deltaEx3 was the lowest ex-
pressed, albeit still at higher levels (up to 20-fold) that of normal
cerebellum. Prior functional studies using exogenous expression
constructs of Survivin-2B and Survivin-deltaEx3 in different cell
lines suggested that Survivin-deltaEx3 protects cells from pro-
grammed cell death, while Survivin-2B enhances programmed cell
death (Islam et al, 2000; Mahotka et al, 2002a,b).
Given the highly malignant nature of medulloblastoma, we
hypothesise that the dominant Survivin isoform expressed in these
tumours has a critical antiapoptotic function. Our data showing
that Survivin, itself, is the highest expressed transcript of all the
isoforms in medulloblastoma tumours is consistent with this
hypothesis. We also hypothesise that Survivin-deltaEx3 likely
functions as an antiapoptotic protein in the formation and
progression of medulloblastoma. As seen in previous studies, the
ratio of Survivin isoforms to each other may be critical for their
functions (Yamada et al, 2003). It will be interesting to quantify the
protein products of each of the Survivin isoforms in medullo-
blastoma once sensitive and specific ELISA assays become
available for Survivin-2B and Survivin-deltaEx3. Targeting the
isoform protein(s) that are most functionally active or tumouri-
genic in a specific tumour may be the most effective anti-Survivin
treatment strategy.
Interestingly, our immunohistochemical staining of primary
medulloblastoma tumours showed a unique nuclear pattern of
expression with each of two different polyclonal anti-Survivin
antibodies tested. Previously published results by our laboratory,
evaluating Survivin expression in normal human brain cells,
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Figure 3 Kaplan–Meier curve of overall survival (OS) in 40 medullo-
blastoma patients, from our study population. The solid line represents OS,
and the dotted lines represent the 95% confidence intervals.
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sbut was predominantly cytoplasmic with the other antibody
(Altura et al, 2003). Immunofluorescent studies performed in
HeLa cells using antibodies directed against specific amino acids
within the Survivin protein have shown that Survivin localises to
different subcellular nuclear and cytosolic structures (Fortugno
et al, 2002). In that study, the nuclear Survivin pool was associated
with kinetochores and was hypothesised to be a potentially
important regulator of the mitotic spindle checkpoint. The
specific nuclear staining pattern found in our medulloblastoma
cases suggests that the function of the Survivin proteins in
medulloblastoma is related to their nuclear localisation, or
perhaps, mislocation to the nucleus.
Among the different morphologic subtypes, the desmoplastic
and extremely nodular medulloblastomas in our study population
had unique Survivin staining patterns with an increased number of
Survivin-positive cells in the internodular zones in areas of poor
neuronal differentiation, as indicated by the arrow in Figure 4C.
Historically, the desmoplastic and extremely nodular subtypes
have improved survival rates, possibly because they are more
differentiated, slower growing, and more sensitive to chemother-
apy and radiation (Packer et al, 1999; Suresh et al, 2003). The high
percentage of internodular Survivin staining in our samples
suggests that Survivin may play an important role in tumourigen-
esis in these tumour subtypes as well.
The large-cell-anaplastic tumours in our study population had a
statistically higher mean percentage of Survivin-positive cells when
compared with the classic medulloblastoma tumours. Histopatho-
logically, the large-cell-anaplastic variant is composed of large
neoplastic cells with large, round, vesicular nuclei, and prominent
nucleoli. There are frequent numbers of mitotic cells, abundant
number of cells undergoing apoptosis, with increased areas of
anaplasia (Brown et al, 2000; Leonard et al, 2001). A Pediatric
Oncology Group (POG) study evaluating medulloblastomas
showed that the large-cell-anaplastic subtype was more likely to
present with malignant cells within the CSF and distant metastasis
compared to non-large-cell tumours. The overall survival of these
Figure 4 Protein expression of Survivin in medulloblastoma tumours. Immunohistochemistry of (A) classic ( 140), (B) large-cell-anaplastic ( 270), (C)
desmoplastic ( 70), and (D) extremely nodular medulloblastoma ( 70) using NB-500-201 antibody. Red staining indicates Survivin-positive cells. Note
the specific nuclear localisation in all of the Survivin-positive cells. The arrow in (C) indicates the high percentage of staining in the internodular areas of a
desmoplastic variant.
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spatients was markedly inferior to non-large-cell medulloblastoma
patients (Brown et al, 2000). Overall, clinical outcomes for patients
with large-cell-anaplastic medulloblastoma are poor, with about a
20% 5-year OS (McManamy et al, 2003). Although we can
subclassify these tumours by histology, thus far, current therapy
has not been successful in eradicating these tumours. Our study
suggests that immunohistochemical staining with Survivin anti-
bodies may be a useful tool to identify the more aggressive large-
cell-anaplastic subtypes. Survivin may be a potential biologic
target in this particular subgroup of patients.
Advances in preclinical anti-Survivin therapies have been
evaluated in numerous tumours and tumour cell lines. Antisense
oligonucleotides to Survivin have shown potential therapeutic
responses in mesothelioma, breast, and lung cancer (Tamm et al,
1998; Olie et al, 2000; Xia et al, 2002). Immune-modulated
therapies have also been evaluated. In a phase I study, an HLA-
A24-restricted antigenic peptide, Survivin 2B80-88, which is
recognised by CD8þ cytotoxic T-lymphocytes, was used to
vaccinate patients with recurrent colorectal cancer. They observed
a decrease in tumour markers in 40% of patients tested and a
reduction in tumour size in one of 15 patients (Tsuruma et al,
2004). These and future Survivin-targeted therapies may be one
element of biologic therapy that would also benefit children with
medulloblastoma.
Our results show that the Survivin proteins are biologic
markers of tumour morphology and clinical outcome in medullo-
blastoma patients, suggesting they may be useful molecular targets
in these tumours. Specific biologic aberrations in medulloblastoma
will become increasingly more important therapeutically as an
attempt is made to decrease the high morbidity associated with
current medulloblastoma treatment strategies. Early studies
evaluating anti-Survivin therapies in other malignancies and
tumour cell lines have shown promising results (Xia et al, 2002;
Tsuruma et al, 2004). The use of novel biologic therapies in
combination with conventional chemotherapy and radiation will
be the future key to decreasing mortality in high-risk patients and
reducing morbidity in all medulloblastoma patients. Our findings
suggest that future large clinical studies of medulloblastoma
should evaluate Survivin and its isoforms as markers of tumour
morphology, predictors of patient outcome, and targets for future
biologic therapies.
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